Section 3 of 6
Product information and disease description
367 evidence topics · 136 sources
Product description
Phase of product development
Summary: regulatory status and development history
- Approval: the FDA approved Lembaz (adrabetadex) injection under NDA 220996 on November 17, 2026, as a “Type 1 - New Molecular Entity” with priority review and orphan status. The FDA describes it as the first treatment shown to help people with a “severe form of Niemann-Pick disease type C (NPC) live longer”. Beren Therapeutics states that LEMBAZ will be available at commercial treatment sites nationwide in early December.
- Application and review: Beren Therapeutics, through its subsidiary Mandos LLC, submitted the NDA on December 17, 2025 for the treatment of patients with infantile-onset NPC. The application was based on an externally controlled survival analysis, biomarker and nonclinical confirmatory evidence, and patient experience narratives. The FDA granted priority review and assigned a PDUFA target action date of August 17, 2026. Beren's March 18, 2026 response to an FDA information request was classified as a major amendment, which extended the goal date by three months to November 17, 2026. The application was not referred to an FDA advisory committee.
- Designations: the FDA designated 2-hydroxypropyl-B-cyclodextrin an orphan drug for the treatment of Niemann Pick disease, type C on 02/18/2013, with Mandos LLC as the sponsor. The European Commission granted orphan designation EU/3/13/1124 on 26 April 2013 to the International Niemann-Pick Disease Alliance; sponsorship was transferred to Vtesse Europe Limited in February 2015, Mallinckrodt Pharmaceuticals Ireland Limited in September 2018, Rapport Global Strategic Services Ireland Limited in December 2021, and Eliquent Life Sciences Limited in August 2024. Adrabetadex also holds rare pediatric disease designation. The FDA granted Vtesse Breakthrough Therapy designation for VTS-270 in Niemann-Pick Type C1 disease on January 6, 2016 and later rescinded it based on data from a 12-month phase 2b/3 trial; a second Breakthrough Therapy designation, for infantile-onset NPC, was announced on December 9, 2025 and was informed by an externally controlled survival analysis.
- Priority review voucher and patents: the FDA granted a rare pediatric disease priority review voucher (PRV NDA 220996) with the approval, which may be transferred, including by sale. Earlier agreements refer to shares of voucher proceeds: Sucampo agreed in 2017 to pay Vtesse shareholders a share of net proceeds from monetization of the voucher, and the Mallinckrodt plan of reorganization refers to the Debtors' 63% retained ownership interest in the voucher. Beren states that its intellectual property estate provides patent protection through 2046, excluding potential patent term extensions, patent term adjustments, and supplementary protection certificates, and that it holds more than 30 issued U.S. patents.
- Development history: researchers at the NIH National Center for Advancing Translational Sciences and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, in collaboration with Vtesse, developed VTS-270. After its launch in January 2015, Vtesse fully enrolled the registrational study at 20 clinical trial sites. Sucampo acquired Vtesse on April 3, 2017 for upfront consideration of $200 million plus contingent royalties, and Mallinckrodt acquired Sucampo, and with it VTS-270, in February 2018. At a Type A meeting in August 2018, the FDA indicated that approvability would be based on the totality of data; in November 2018 Mallinckrodt announced that the registration trial did not show a statistically significant separation from placebo. In the three months ended December 27, 2019, Mallinckrodt recognized a full impairment of $274.5 million on the VTS-270 asset, “primarily driven by continued regulatory challenges”, and trial NCT03643562 ended after the sponsor determined that the benefit-risk profile of adrabetadex was not favorable. Mandos acquired the program from Mallinckrodt in 2021, held an introductory call and a Type C meeting with the FDA, and completed new analyses of adrabetadex before the NDA submission.
- Earlier timelines: in April 2017 Sucampo expected pivotal trial results in mid-2018 and a launch beginning in 2019, and a YODA Project data request projected an NDA submission by December 2023 toward accelerated approval.
Regulatory status: Approved; NDA submitted December 2025 and approved November 2026
| Action date | Submission | Action type | Submission classification | Review priority; orphan status |
|---|---|---|---|---|
| “11/17/2026” | “ORIG-1” | “Approval” | “Type 1 - New Molecular Entity” | “PRIORITY; Orphan” |
Launch: Approved November 2026, with commercial availability expected in early December 2026
FDA approval in November 2026
Review timeline: major amendment and three-month extension of the goal date
Basis of the application: externally controlled survival analysis with confirmatory evidence
Expedited programs: priority review
Breakthrough Therapy designation for infantile-onset disease, December 2025
Breakthrough Therapy designation of January 2016, later rescinded
Orphan drug designation in the United States, February 2013
| Field | Quoted record |
|---|---|
| Generic name | “2-hydroxypropyl-B-cyclodextrin” |
| Date designated | “02/18/2013” |
| Orphan designation | “Treatment of Niemann Pick disease, type C.” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Mandos LLC” |
Orphan designation in the European Union, April 2013, and transfers of sponsorship
Rare pediatric disease designation
Rare pediatric disease priority review voucher granted at approval
Priority review voucher proceeds: interests retained by earlier owners
Patent estate statements, August 2026
Development history: origin at the National Institutes of Health and Vtesse
Development history: acquisition of Vtesse by Sucampo, April 2017
Development history: acquisition of Sucampo by Mallinckrodt, February 2018
Development history: phase 2b/3 result and FDA Type A meeting, 2018
Development history: full impairment of the VTS-270 asset, December 2019
Development history: termination of the open-label trial under the prior sponsor
Development history: transfer of the product from Mallinckrodt to Mandos, 2021
Development history: FDA meetings under Mandos, 2022 to 2024
PDUFA target action date of August 17, 2026, February 2026, superseded in May 2026
FDA decision timing, December 2025, superseded in February 2026
NDA submission timing, December 2025, superseded in December 2025
NDA submission timing, October 2025, superseded in December 2025
NDA submission timing and accelerated approval plan, 2021, superseded in December 2025
Pivotal results timing, April 2017, superseded in November 2018
Launch timing, April 2017, superseded in November 2018
Product information
Generic, brand name and therapeutic class of product
Generic name and brand name
“LEMBAZ™ (adrabetadex) injection, for intrathecal use” (opens the source at this quote in a new tab)
| Drug name | Active ingredients | Strength | Dosage form/route | Marketing status |
|---|---|---|---|---|
| “LEMBAZ” | “ADRABETADEX” | “900MG/4.5ML (200MG/ML)” | “INJECTION;SOLUTION” | “Prescription” |
Development code and synonyms: VTS-270 and 2-hydroxypropyl-β-cyclodextrin
Manufacturer: Mandos LLC, a subsidiary of Beren Therapeutics
Therapeutic class: 2-hydroxypropyl-substituted beta cyclodextrin
Dosage forms and strengths
Injection: strength and appearance
Composition, inactive ingredients, and pH
Package and national drug code
| Package | NDC number | Strength | Contents |
|---|---|---|---|
| Carton | “Carton: 87230-101-01” | “900 mg/4.5 mL” | “One single-dose vial in a carton” |
| Vial | “Vial: 87230-101-02” | “900 mg/4.5 mL” | “One single-dose vial in a carton” |
Material safety data sheet
No evidence found.
Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
- Price basis: no wholesale acquisition cost (WAC) or list price for adrabetadex (Lembaz) had been published as of 18 November 2026, the date of the latest source; trade press reporting on the approval states that list pricing had not been announced.
- Dosing basis: per the prescribing information, adrabetadex is supplied as one 900 mg/4.5 mL single-dose vial per carton and is administered intrathecally every two weeks, with an age-based starting dose and upward titration to a weight-based maximum of 600 mg every two weeks (7 kg to less than 12 kg) or 900 mg every two weeks (12 kg or more). Every labeled dose is at or below 900 mg, so each administration uses one vial, assuming a whole vial per administration as the label gives no other basis. Every two weeks is 26 administrations, and therefore 26 vials, per year; the manufacturer's out-of-pocket program terms also cap support at 26 doses per year.
- Base case: not calculable, because no price has been published.
- Range: not calculable. With one vial per administration, annual drug cost will equal 26 times the vial price at every labeled dose and weight band, and monthly cost will equal annual cost divided by 12.
- Rationale for the range: the label varies the dose by age, body weight, audiology results, and dose reductions for ataxia or fatigue, but no labeled dose exceeds the content of one vial, so these sources of variation change the volume administered and leave the number of vials unchanged under the whole-vial assumption.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
Wholesale acquisition cost: not announced at approval
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
ATC classification
No evidence found.
Indication
Approved indication
FDA and company descriptions of the approved population
Pharmacology
Mechanism of action
Mechanism of action: prescribing information
Mechanism of action: manufacturer description at approval
Restoration of cholesterol trafficking in the central nervous system: company nonclinical studies
Cyclodextrins as lipid-mobilizing agents
“Recently, uncomplexed cyclodextrins have emerged as potent therapeutic compounds in their own right, based on their ability to sequester and mobilize cellular lipids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In particular, 2-hydroxypropyl-β-cyclodextrin (HPβCD) has garnered attention because of its cholesterol chelating properties, which appear to treat a rare neurodegenerative disorder and to promote atherosclerosis regression related to stroke and heart disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Cerebrospinal fluid biomarkers after 52 weeks of treatment
Target engagement in mouse and cat models: company nonclinical studies
Intracisternal administration in cats with Niemann-Pick disease type C1
“In contrast, direct administration of HPβCD into the cisterna magna of presymptomatic cats with NPC disease prevented the onset of cerebellar dysfunction for greater than a year and resulted in a reduction in Purkinje cell loss and near normal concentrations of cholesterol and sphingolipids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, administration of intracisternal HPβCD to NPC cats with ongoing cerebellar dysfunction slowed disease progression, increased survival time, and decreased the accumulation of brain gangliosides.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Plasma pharmacokinetic parameters after intrathecal administration
| Parameter, mean (CV%) | 200 mg | 300 mg | 600 mg | 900 mg |
|---|---|---|---|---|
| AUC0-last (hr·mcg/mL) | “39 (19%)” | “51 (14%)” | “101 (34%)” | “167 (40%)” |
| Cmax (mcg/mL) | “2.4 (33.7%)” | “4.5 (77.3%)” | “6.3 (37%)” | “8.4 (84.3%)” |
Absorption, distribution, and elimination
Cerebrospinal fluid and plasma pharmacokinetics after intracerebroventricular dosing in the NIH phase 1 trial
“Three NPC1 subjects were admitted to the NIH Clinical Center Intensive Care Unit and an Ommaya reservoir was surgically placed on the nondominant side.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following the ICV injection of 50 mg HP-β-CD, high CSF concentrations of HP-β-CD were observed with the Cmax ranging from approximately 520 to 1,500 μg/ml in three patients (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean Vdss of ∼130 ml was approximately to the reported CSF volume in humans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated mean t1/2 for HP-β-CD in CSF was 6.58 h based on the RP-UPLC-MS/MS method and 10.1 h based on the 2D-LC-IF-MS/MS method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean Cmax and AUC of HP-β-CD in plasma were less than 0.3% of the corresponding CSF PK parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated mean t1/2 values for HP-β-CD in plasma were 12.4 h based on the RP-UPLC-MS/MS method and 15.1 h based on the 2D-LC-IF-MS/MS method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system distribution after a single intrathecal dose in cats
“In this study, tissue distribution was investigated in normal cats that received a single 120‐mg dose of [14C]‐HP‐β‐CD (approximately 200 μCi/cat) via the cerebellomedullary cistern (CBMC) and lumbar cistern.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HP‐β‐CD‐derived radioactivity penetrated into the deeper parts of the central nervous system with the highest concentration at 4 hours (403 μg Eq/g or 0.28 mM) and remained high (49.7 μg Eq/g or 0.03 mM) at 24 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The relatively long half‐life (11‐30 hours) in cerebral ventricles and the subarachnoid space surrounding the brain and spinal cord might contribute to the efficacy of HP‐β‐CD in NPC1 cats.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Brain distribution and duration of exposure in mice and cats: company nonclinical studies
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Boxed warning: hearing impairment including permanent hearing loss
Hearing impairment: warning and precaution
Hearing impairment with audiometry-guided titration in Trial 3 and the expanded access program
Ataxia: warning and precaution
Fatigue: warning and precaution
Safety population and most common adverse reactions
Common adverse reactions through Week 52 in Trial 1 Parts A and B
| Preferred term | Adrabetadex up to 900 mg (N=32), n (%) | Sham (N=18), n (%) |
|---|---|---|
| Hearing impairment | “23 (71.9)” | “8 (44.4)” |
| Ataxia | “22 (68.8)” | “5 (27.8)” |
| Fatigue | “18 (56.3)” | “5 (27.8)” |
| Vomiting | “17 (53.1)” | “3 (16.7)” |
| Back pain | “16 (50.0)” | “3 (16.7)” |
| Headache | “14 (43.8)” | “3 (16.7)” |
| Pyrexia | “13 (40.6)” | “3 (16.7)” |
| Diarrhea | “10 (31.3)” | “1 (5.6)” |
| Nausea | “8 (25.0)” | “1 (5.6)” |
| Cough | “8 (25.0)” | “4 (22.2)” |
| Contusion | “6 (18.8)” | “2 (11.1)” |
| Pain in extremity | “6 (18.8)” | “1 (5.6)” |
| Epistaxis | “5 (15.6)” | “1 (5.6)” |
| Urinary incontinence | “5 (15.6)” | “1 (5.6)” |
| Muscular weakness | “5 (15.6)” | “0 (0)” |
| Dysarthria | “4 (12.5)” | “1 (5.6)” |
| Skin abrasion | “4 (12.5)” | “1 (5.6)” |
| Nasopharyngitis | “4 (12.5)” | “2 (11.1)” |
Adverse reactions in participants less than 4 years of age
Onset and duration of ataxia and fatigue events
Aspiration pneumonia, including one fatal event after administration with sedation
Overdosage at 1,200 mg and 1,800 mg
Nonclinical carcinogenicity and mutagenicity
Patient counseling on hearing impairment, ataxia, and fatigue
Ototoxicity of 2-hydroxypropyl-beta-cyclodextrin across species: review
“Despite the potential health benefits, use of HPβCD has been linked to significant hearing loss in several species, including humans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ototoxicity can occur following central or peripheral drug delivery, with either route resulting in the preferential loss of cochlear outer hair cells (OHCs) within hours of dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The long-term impact of HPβCD use as a maintenance drug, and the mechanism(s) of ototoxicity, are unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Yet, Kleptose HPB (aka VTS-270) is ototoxic in mice and humans (Davidson et al., 2016; Ory et al., 2017).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, seemingly innocuous doses can become devastating to the ear if administered by different routes close in time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk for functionally significant hearing loss before development of speech and language should be weighed carefully with potential benefits of early-life treatment of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hearing threshold elevation with intracisternal administration in cats
“An increase in hearing threshold was identified as a potential adverse effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our studies in the cat indicate that chronic HPβCD at therapeutic doses is always accompanied by severe hearing loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings have important implications for clinical use in human patients where deafness may be an expected outcome of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events after repeated lumbar puncture for intrathecal delivery at Rush University Medical Center
“Of the 59 patients treated 33 (55.9%) had no adverse events ever after an LP and 26 (44.1%) had adverse effects at some time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 2935 LPs, adverse events occurred after 3.3% of LPs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events most observed were headache (1.2% of LPs), nausea (0.3%), vomiting (1.0%), and back pain (1.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study shows that frequent repeated LPs are possible for delivery of intrathecal therapy and can be accomplished with a very low rate of post-LP adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Special populations
Pregnancy
Lactation
Females and males of reproductive potential: fertility in rats
Pediatric use: established and not established populations
Juvenile animal toxicity: hearing loss in cats and kidney findings in rats
Renal and hepatic impairment
Drug/Drug, drug/disease interactions
Effects of other drugs on Adrabetadex
In vitro cytochrome P450 and transporter substrate studies
Effects of Adrabetadex on other drugs
In vitro transporter inhibition
Binding of arimoclomol and levacetylleucine by adrabetadex: company in silico and in vitro studies
Dosing and administration
Dosage
Upward titration and maximum dosage by weight
Dosage modifications for hearing loss: audiology schedule
Dosage titration recommendations based on audiology results
| Baseline hearing status | Result permitting an increase (first criterion) | Result permitting an increase (alternative criterion) | Result precluding an increase |
|---|---|---|---|
| No baseline hearing impairment | “No hearing impairment observed at frequencies below 4,000 Hz” | “Hearing impairment observed but with a hearing threshold less than or equal to 40 dB HL at frequencies below 4,000 Hz” | “Hearing impairment with a threshold greater than 40 dB HL at frequencies below 4,000 Hz (hearing impairment in the speech hearing range)” |
| Baseline mild to moderate hearing impairment | “No hearing threshold shift at 2 consecutive frequencies below 4,000 Hz” | “Hearing threshold shift that is not greater than 15 dB at 2 consecutive frequencies below 4,000 Hz” | “Hearing threshold shift of greater than 15 dB at 2 consecutive frequencies below 4,000 Hz” |
Dosage modifications for ataxia or fatigue
Missed doses
Administration
Baseline audiology before the first dose
Route and administering provider
Preparation and dilution
Premedication: local anesthesia and sedation
Lumbar puncture technique and positioning after injection
Needles and anesthesia used for repeated lumbar punctures at Rush University Medical Center
“Intrathecal delivery of 2-hydroxypropyl-beta-cyclodextrin (VTS-270, adrabetadex) by lumbar puncture (LP) has been performed on a biweekly schedule for over nine years for the treatment of Niemann-Pick type C1 (NPC1) at Rush University Medical Center.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over this time 59 patients with NPC1 have been treated with 2935 infusions, performed with either a 22-G 3-inch Whitacre or a 22-G 2-inch Gertie Marx atraumatic needles, with or without general anesthesia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Access and distribution
Commercial availability and treatment site coordination
Transition from the Expanded Access Program to commercial treatment
Medical buy-and-bill and billing codes
Prior authorization documentation
Enrollment form
Patient support program: LEMBAZ Family Support
Out-of-pocket, bridge, and patient assistance program terms
Co-prescribed/Concomitant therapies
Combination treatment: 2025 international consensus guideline
“Statement #18: Combination treatment should be considered for all patients with a confirmed diagnosis of NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, available treatments have distinct mechanisms of action, making combination therapy an approach that targets multiple aspects of NPC neuropathology” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite this, it is important to note that healthcare system resource limitations often restrict access to combination treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant arimoclomol, levacetylleucine, and miglustat in the expanded access program
Safety of combination therapy in the expanded access program
Combination with arimoclomol or levacetylleucine in vitro: company nonclinical study
Effect of Adrabetadex on quality measures
Service quality metrics for lysosomal storage disorders: time to disease-modifying therapy, palliative care review, and advance care planning
Product-specific effect on quality measures
No evidence found.
Product comparison
Approval basis and labeled population compared with the two other approved NPC treatments
Arimoclomol: U.S. indication
Arimoclomol: recommended oral dosage by actual body weight, in combination with miglustat
| Actual body weight | Prescribing information |
|---|---|
| 8 kg to 15 kg | “8 kg to 15 kg, is 47 mg three times a day” |
| More than 15 kg to 30 kg | “15 kg to 30 kg, is 62 mg three times a day” |
| More than 30 kg to 55 kg | “30 kg to 55 kg, is 93 mg three times a day” |
| More than 55 kg | “55 kg, is 124 mg three times a day” |
Arimoclomol: dosage forms, packaging, and national drug codes
| Strength | Package configuration | NDC |
|---|---|---|
| 47 mg | “Bottle of 90 capsules” | “72542-147-01” |
| 62 mg | “Bottle of 90 capsules” | “72542-162-01” |
| 93 mg | “Bottle of 90 capsules” | “72542-193-01” |
| 124 mg | “Bottle of 90 capsules” | “72542-124-01” |
Arimoclomol: oral and feeding tube administration
Arimoclomol: warnings and precautions
Arimoclomol: adverse reactions in Trial 1
Arimoclomol: adverse reactions in at least 8% of treated participants who also received miglustat in Trial 1
Arimoclomol: drug interaction with OCT2 substrates
Arimoclomol: pediatric and geriatric use
Levacetylleucine: U.S. indication in Niemann-Pick disease type C
Levacetylleucine: basis of the dosage and packet strength
Levacetylleucine: granules for oral suspension, strength and appearance
Levacetylleucine: warning for embryo-fetal toxicity
Levacetylleucine: adverse reactions in NPC, safety population and exposure in Trial 1
Levacetylleucine: rosacea and thrombocytopenia in NPC Trial 1
Levacetylleucine: pediatric use in NPC and supporting pharmacokinetic data
Miglustat: U.S. labeled indication limited to type 1 Gaucher disease
Miglustat: European Union indication and dosage in Niemann-Pick type C disease
Miglustat: European Union dose by body surface area in Niemann-Pick type C disease, patients under 12 years
| Body surface area (m2) | Recommended dose |
|---|---|
| More than 1.25 | “200 mg three times a day” |
| More than 0.88 to 1.25 | “200 mg twice a day” |
| More than 0.73 to 0.88 | “100 mg three times a day” |
| More than 0.47 to 0.73 | “100 mg twice a day” |
| 0.47 or less | “100 mg once a day” |
Miglustat: European Union dose in renal impairment
Miglustat: European Union contraindications, warnings, and precautions
Miglustat: most common adverse reactions in European Union labeling
Remibetadex (intravenous hydroxypropyl-beta-cyclodextrin, Trappsol Cyclo): investigational status and proposed use
Place of product in therapy
Disease description
Definition and etiology
Guideline definition: autosomal recessive neurovisceral lysosomal disorder
“Statement #1: NPC is a progressive and life‐limiting autosomal recessive, neurovisceral lysosomal disorder caused by pathological variants in either NPC1 or NPC2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Variants in these genes are associated with abnormal endosomal‐lysosomal trafficking, resulting in the accumulation of unesterified cholesterol and other lipids in the lysosomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease onset varies, ranging from antenatally to throughout the lifespan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic basis and diagnostic definition
Autosomal recessive inheritance and recurrence risk
Genetic etiology and clinical forms by age at onset
“Niemann-Pick disease type C (NPC) is an autosomal recessive disorder caused by pathogenic variants in NPC1 (OMIM 257220, HGNC:7897) or NPC2 (OMIM 607625, HGNC:14537)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The infantile-onset form of NPC is characterized by cholestatic liver disease, hepatosplenomegaly, and pulmonary infiltrates, whereas later presentations include progressive neurologic symptoms, including cognitive impairment, cerebellar ataxia, psychiatric manifestations, and seizures, in addition to visceral disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition of infantile-onset NPC: sponsor statement
Classification by age at onset of neurological manifestations
“Nevertheless, NPC is best classified according to the age at onset of neurological manifestations, as this correlates with prognosis, as follows:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pre/perinatal (< 2 months)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Early infantile (2 months–2 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Late infantile (2–6 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Juvenile (6–16 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adult (> 16 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Alternative onset-category thresholds in a registry-based survival study
“Miglustat‐treated and untreated patients overall and within sub‐groups according to age‐at‐neurological‐onset, that is, early infantile‐onset (<2 years), late infantile‐onset (2 to <6 years), juvenile‐onset (6 to <15 years), and adolescent/adult‐onset (≥15 years) were analysed and compared.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Niemann-Pick disease type C
Guideline incidence estimate and range across national studies
“Statement #2: NPC disease is ultra‐rare, with an estimated incidence of one case per 100 000 live births.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The disease is pan‐ethnic, with at least 95% of all cases attributed to variants in NPC1, and the remainder in NPC2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The milder forms of the disease remain underdiagnosed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retrospective, national expert center‐based studies from Australia, the Netherlands, the UK, Portugal, the Czech Republic, France, and the United Arab Emirates have reported an annual incidence varying between 0.25 and 2.20 per 100 000 live births” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incidence predicted from exome sequencing data sets
“We determined a combined incidence of classical NPC of 1/89,229 or 1.12 affected patients per 100,000 conceptions, but predict incomplete ascertainment of a lateonset phenotype of NPC1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our data suggests an incidence rate for NPC1 and NPC2 of 1/92,104 and 1/2,858,998, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, evaluation of common NPC1 variants, suggests that there may be a late-onset NPC1phenotype with a markedly higher incidence on the order of 1/20,000–39,000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incidence in France
Minimal incidence and birth prevalence by country
“Niemann-Pick C disease (NP-C) is a neurovisceral atypical lysosomal lipid storage disorder with an estimated minimal incidence of 1/120 000 live births.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimates of birth prevalence ranging between 0.66 and 0.83 per 100,000 were proposed for France, the UK and Germany based on diagnoses made in the laboratory of the author over the period 1988-2002” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Birth prevalence by country and in Quebec
“Elsewhere in the world, the prevalence of NP-C for 100,000 live births is 0.47 in Australia44, 0.91 in Czech Republic15, 2.2 in Northern Portugal4, 0.35 in the Netherlands3, 0.82 for France5, 0.78 for the United Kingdom45 and 1.12 for the United States of America (USA)46.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By combining these different prevalences, we obtain an average of 0.95 cases per 100,000 births.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimate a prevalence of 0.61 per 100,000 births in Quebec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated new cases per year in the United States
Distribution of clinical forms in eight national and international cohorts
Regional variation in the early infantile form
“Two features emerge from the compiled data presented in Table 1: the early infantile neurological onset form appears more frequent in Southern Europe and the Middle East, and patients with the adult‐onset neurological form seem to represent at least 20% of the cases of NPC and, owing to their longer survival, probably constitute the largest patient group in terms of disease prevalence” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution by age at neurological onset: International Niemann-Pick Disease Registry
“A total of 203 NPC patients from six European countries were included in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among enrolled patients, 168 had known neurological manifestations: 43 (24.2%) had early-infantile onset, 47 (26.4%) had late-infantile onset, 41 (23.0%) had juvenile onset, and 37 (20.8%) had adult onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“10 (5.6%) patients had the neonatal rapidly fatal systemic form.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution by age at neurological onset: pooled national cohorts and NPC Registry
“Data for 789 patients from five large national cohorts and from the NPC Registry were collected and combined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Neurological onset group comprised 97 early infantile, 210 late infantile, 198 juvenile, and 163 adolescent/adult patients (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution by age at neurological onset: NPC Registry at closure
“At database closure, 472 patients from 22 countries were enrolled in the NPC Registry (see Additional file 1), with a similar proportion of males (n = 245; 51.9%) and females (n = 227; 48.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with known age at onset of neurological symptoms (n = 422) were categorized as early-infantile (n = 57; 13.5%), late-infantile (n = 108; 25.6%), juvenile, (n = 134; 31.8%), or adolescent/adult (n = 123; 29.1%) onset (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early infantile neurological onset among patients diagnosed in France, 1990 to 2013
“During the period 1990–2013, a total of 153 new patients with NP-C (from perinatal period to adulthood) were diagnosed in France, among which 32 patients (21%) with neurological onset before 2 years of age, who were thus classified as suffering from the EI neurological form of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Niemann-Pick disease type C
United States diagnosed and estimated prevalence from claims data
“A total of 308 million unique individuals were represented in the database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 294 individuals had an NPC diagnosis, yielding an identified NPC prevalence of 0.95 per million people in the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“305 individuals were diagnosed with NPC and/or were treated with miglustat without having a diagnosis for either Gaucher or GM1 gangliosidosis, yielding an NPC diagnosed or treated prevalence of 0.99 per million people in the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Applying this number to the distribution of NPC type (based on age of neurologic symptom onset) and corresponding mortality estimates generates an estimated 943 prevalent cases of NPC, or 2.9 cases of NPC per million people in the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States claims analysis: data source, methods, and author affiliations
“For the first two objectives, patients were identified using the Symphony Integrated DataVerse database (Oct 2015-Jan 2020).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the third objective, published NPC incidence (1 per 89,000 live births) and expected mortality estimates were applied to the 2018 United States birth rate (11.6 per 1000) and population size (326.7 million).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Blair Orr, Shilpa Chatlani, Kwangchae Yoon, and Dan Gallo are shareholders and employees of Orphazyme USA Inc.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Infantile-onset share of United States prevalent cases: sponsor statement
Undiagnosed fraction in the United States: sponsor statement
Prevalence estimates in Western Europe and the United States
Oregon Medicaid drug evaluation statement of frequency
Share of adult-onset disease among prevalent cases
Diagnosed cases in Australia
“In the absence of a national register, the number of current diagnosed cases in Australia is estimated by clinical services as between 25 and 33, although this is widely considered an underestimate, with many cases likely undetermined or in some cases misdiagnosed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Life expectancy by age at neurological onset
“Life expectancy among patients with NPC disease varies depending on the age at neurological symptom onset, ranging from a few days to many decades” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from a large cohort of French NPC patients and the INPDR indicate that the age at onset of neurological symptoms predicts disease severity and life expectancy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The acute pre/perinatal form (fetal hydrops or ascites, early liver, multi‐organ failure, and in some cases, respiratory failure), which usually results in death before the age of 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA statement on infantile-onset disease severity
Mean ages of death in infantile onset: sponsor statement
Mean age of death by onset category in a United Kingdom cohort, and survival after diagnosis
“Imrie, et al. [6] published a report of 74 patients in a United Kingdom cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the neonatal onset group the mean age of death (± SD) was 0.19 ± 0.22 years, in the early-infantile group mean age of death was 5.6 ± 2 years, in the late infantile group the mean age of death was 13.4 ± 6.7, and in the juvenile onset group the mean age of death was noted to be 25.9 ± 8.9 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adolescent /adult group had a mean age of death of 33.7 ± 6.2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty percent of NPC patients with neurological onset either prior to 2 years or between 2-11 years of age died within approximately 3 or 7 years of diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at death across all onset categories: 338 deceased individuals
“Median age of death for this cohort was 13 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The histograms clearly show a marked increase in deaths starting at 4 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median ages of death for these four-time intervals were 5, 12, 13, 14 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Except for the first time period, where the number of subjects was very low, there did not appear to be a significant increase in survival from 1998 to 2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Median ages at diagnosis and death by onset category: International Niemann-Pick Disease Registry
“Data on the age at diagnosis and age at death was available for 59 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with the early infantile form (N = 17), the median ages at diagnosis and death were 1.8 years (0.3–17.0) and 5 years (0.8–22.0), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with the late infantile form (N = 17), the median ages at diagnosis and death were 4.4 years (0.1–8.8) and 8.8 years (5.0–16.0) respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Untreated early infantile onset in France: median survival
“In the untreated group, the median survival was 4.42 years, with an age at death comprised between 3.1 and 6.5 years for 12 patients; 4 patients were unfortunately lost to follow-up when aged 2.9 to 3.3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No patient was alive beyond the age of 7 years 5 months in either group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Crude death rates during periods without miglustat, by onset category
Survival by onset category in registry-based analyses
“The age of neurological manifestation onset has been recognised as a predictor for severity, rate of disease progression, and life expectancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Survival appears to be the poorest in patients with rapidly progressive early infantile neurological onset, whereas patients with more slowly progressive adult onset NP‐C tend to live longer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Course of the early infantile and late infantile forms
“Delay of developmental motor milestones from the age of 8-9 months and central hypotonia constitute the first neurologic symptoms, which become evident between the age of 1 and 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many of these children never learn to walk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Survival rarely exceeds 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The child often presents with gait problems, frequent falls and clumsiness between 3 and 5 years of age, due to ataxia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Death most often occurs between 7 to 12 years in this form.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, the lifespan of the patients varies between a few days until over 60 years of age, although a majority of cases die between 10 and 25 years of age” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lifespan by phenotypic form: Oregon Medicaid drug evaluation
United States National Niemann-Pick C1 disease database: ages at diagnosis and death
“The present study provides basic clinical and health information from the National Niemann-Pick C1 disease database that was obtained using a clinical questionnaire of 83 questions mailed to families affected by NPC1 disease living in the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average age of diagnosis for NPC1 disease was 10.4 years, with one-half of patients being diagnosed before the age of 6.9 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average age of death for NPC1 disease was 16.2 years, with one-half of patients dying before the age of 12.5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age range of death across the disease spectrum
“Niemann-Pick Disease Type C (NPC) is an ultra-rare progressive neurodegenerative disease caused by autosomal recessive mutations in the NPC1 or NPC2 genes that lead to premature death, with most individuals dying between 10 and 25 years of age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cause of death: aspiration pneumonia and bronchopneumonia
“The most common cause of death in individuals with neurological symptoms is aspiration pneumonia preceded by dysphagia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Epidemiological data suggest that bronchopneumonia subsequent to food or fluid aspiration is a major cause of mortality in NP-C and other neurodegenerative disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While precise causes of death are not consistently reported in NP-C, two studies have identified bronchopneumonia as the leading cause of death in two separate NP-C patient cohorts, accounting for approximately two-thirds of patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rate of neurological progression in a prospective observational cohort
“Of the 36 individuals with NPC (2–18 years) enrolled, 31 (86.1%) completed the 6–14-month observation period; 30/36 (83.3%) were receiving miglustat as part of routine clinical care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (± SD) increase in the total 5-domain NPCCSS was 1.4 (± 2.9), representing a mean (± SD) change per 6 months of 0.75 (± 1.58; annualized progression = 1.5 points) (Fig. 3a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
NPC1 and NPC2 proteins in lysosomal cholesterol trafficking
“These proteins work sequentially to facilitate the bidirectional cellular trafficking of cholesterol and other lipids from the lysosome to the endoplasmic reticulum” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Variants that cause disease in either gene lead to tissue accumulation of multiple lipids” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Functions of the NPC1 and NPC2 proteins
“NPC1 is an integral membrane protein that facilitates the transport of cholesterol across the endolysosomal membrane, and NPC2 is a non-enzymatic soluble lysosomal protein that likely transports cholesterol from the lysosomal lumen to NPC1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Impaired function of either NPC1 or NPC2 leads to an endolysosomal accumulation of cholesterol and glycosphingolipids” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecular pathogenesis: loss of function and lysosomal lipid accumulation
Cellular hallmark and its reversal by 2-hydroxypropyl-beta-cyclodextrin in cultured cells
“In Niemann-Pick C disease cells (either NPC1 or NPC2), the cholesterol does not exit the endocytic pathway but accumulates within lysosomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This anomaly constitutes the cellular hallmark of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Very recently, it was further shown that the block in cholesterol delivery to the ER can also be overcome by 2-hydroxypropyl-beta-cyclodextrin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuronal pathogenesis
“The pathogenesis of the neuronal dysfunction appears by far more complex, since brain cholesterol is synthesized locally, mostly by oligodendroglial cells and to a lesser extent by astrocytes and neurons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, since abnormal filipin staining of neurons is also observed in a wide spectrum of other lysosomal storage disorders [discussed in 63], the exact participation of cellular cholesterol transport abnormalities in the pathophysiology of the neurodegenerative NP-C disease remains elusive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genotype and early-onset disease
Cholesterol trafficking defect and genotype: Oregon Medicaid drug evaluation
Diagnosis
Guideline statements on suspicion, biomarker screening, and genetic confirmation
“Statement #9: The signs and symptoms of NPC are nonspecific, which may lead to misdiagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the presence of cataplexy and/or saccadic eye movement abnormalities should raise suspicion of NPC and help differentiate NPC from other neurodegenerative disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #12: Biomarker assessment should be considered the first‐line test to screen for NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three classes of biochemical markers are currently in use (oxysterols, PPCS, and lyso‐SM) or development (bile acid derivatives).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Typically, the diagnosis must be confirmed by deoxyribonucleic acid (DNA) sequencing, although diagnostic routes depend on tool availability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #13: Any individual whose diagnosis of NPC is considered based on their clinical manifestation and/or abnormal biomarker profile should undergo genetic testing for NPC genes to confirm the diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Referral to a clinical geneticist or genetic counselor should be considered following NPC diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Biomarkers: oxysterols, PPCS and lyso-SM, and bile acids
“The oxysterols cholestane‐3β, 5α, 6β‐triol (C‐triol) and 7‐ketocholesterol (7‐KC) are sensitive markers of NPC, though C‐triol is more specific” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Striking elevations of PPCS have been reported in both NPC and ASMD, with high sensitivity for detecting both disorders but poor distinction between them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A high PPCS/lyso‐SM ratio appears to be very specific to NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is highly sensitive and more specific than oxysterols (only elevated in ASMD and NPC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic testing: variant spectrum and limits of routine sequencing
“Genetic testing (NPC1 and NPC2) is recommended to confirm NPC diagnosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, some genetic changes (e.g., deep intronic variants, complex structural variants) may not be identified by routine sequencing methods and require complementary testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The identification of two alleles with known disease‐causing variants in either the NPC1 or NPC2 gene confirms the diagnosis of NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To date, about 700 different NPC1 variants have been reported, among which around 420 are considered pathogenic, with only a limited number of common or recurrent (often in certain populations) variants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suspicion Index screening tools
“The Niemann‐Pick disease type C Suspicion Index (NPC‐SI) has been developed as a simple, interactive screening tool to assist HCPs in the early identification and referral of individuals suspected of NPC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NPC‐SI includes two age‐specific screening tools: one for individuals older than 4 years and another for individuals younger than four (early‐onset NPC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early-onset Suspicion Index for children aged 4 years or younger
“An early-onset NP-C SI was constructed following retrospective chart review of symptom presentation in 200 patients from nine centres comprised of 106 NP-C cases, 31 non-cases and 63 controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Visceral symptoms were amongst the strongest predictors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Except for gelastic cataplexy and vertical supranuclear gaze palsy, central nervous system symptoms were not discriminatory in this population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The early-onset NP-C SI can help physicians, especially those with limited knowledge of NP-C, to identify patients aged ≤4 years who warrant further investigation for NP-C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical findings by age group and first-line laboratory tests
Molecular testing approaches
Neonatal cholestasis as a presentation of NPC
PPCS biomarker performance
“Blood‐based biomarkers have replaced filipin staining.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PPCS‐based assays now offer 100% sensitivity, 96.6% specificity in identifying NP‐C1 cases from controls and NP‐C1 carriers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay by age at neurological onset: NPC Registry
“A diagnostic delay was apparent in each of these age at neurological onset categories, with a mean delay between the appearance of first neurological symptoms and a confirmed diagnosis of NP-C of 2.5 years in early-infantile, 4.3 years in late-infantile, 6.2 years in juvenile, and 6.3 years in adolescent/adult patients (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay in pooled cohorts
Mean age at diagnosis: International Niemann-Pick Disease Registry
Diagnostic challenges and consequences
“Challenges also remain in differential diagnosis, prolonged times to diagnosis, and in some cases, misdiagnosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consequently, NPC patients may encounter delayed or restricted access to suitable management strategies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor diagnostic program: Test for NPC and NPC GenomeComplete
Newborn screening: status and bile acid dried blood spot assay
“Newborn screening has the potential to enable earlier diagnosis prior to the onset of neurological symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NP‐C is not currently included in the Australian newborn screening programmes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A high-throughput, mass spectrometry-based method was developed and validated to measure the glycine-conjugated bile acid in dried blood spots.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of dried blood spots from 4992 controls, 134 NPC carriers, and 44 NPC subjects provided 100% sensitivity and specificity in the study samples.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To address this critical question, we obtained the newborn DBS for already diagnosed NPC1 subjects (n=15) and carriers (n=3) residing in California, New York, and Michigan, states that archive residual DBS in biorepositories.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bile acid B, the more specific biomarker for which the fully validated DBS assay was developed, was detected in 8/15 NPC1 patients, and elevated above the cut-off in 2/15 patients (the two samples with the shortest storage time).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results demonstrate that newborn screening for NPC1 disease is feasible using bile acid biomarkers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
New York pilot newborn screening study listing NPC among its conditions
Clinical presentation - signs and symptoms
Age-dependent presentation: visceral in infancy, neurological from late infancy onward
Hepatic and visceral symptoms: neonatal cholestasis and hepatosplenomegaly in the pre/perinatal period
“Statement #4: NPC primarily manifests in the pre/perinatal age group as liver disease presenting with prolonged cholestatic jaundice, hepatosplenomegaly, and in some cases fetal hydrops or ascites and acute liver failure, with or without pulmonary disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In most cases, jaundice resolves spontaneously by 3–4 months of age, while organomegaly persists to variable degrees.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic and visceral symptoms: frequency of splenomegaly, hepatomegaly, and neonatal jaundice in the International Niemann-Pick Disease Registry
“Here we report NPC patient data from the International Niemann-Pick Disease Registry (INPDR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients who developed splenomegaly was 72.8%, whilst hepatomegaly was reported in 39.5% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, neonatal jaundice was noted in 39.5% of patients, and hepatic failure in the neonatal period was 6.2%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients with neonatal jaundice, spleno- and hepatomegaly decreased with increasing age of neurological onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic and visceral symptoms: neonatal liver disease and earlier neurological onset in 93 individuals with NPC1
“Liver disease was characterized in 93 individuals with NPC1 using FibroScan, abdominal ultrasound, and plasma liver function tests at baseline and longitudinally over up to a four-year period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Those with no history of neonatal liver disease had an average age of 10.3 years at time of neurological symptoms, compared to 5.9 years for those with mild/moderate disease and 3.6 years for those with severe disease (p = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory symptoms: pulmonary foam-cell infiltration in infancy
Motor and developmental symptoms: hypotonia and delayed motor milestones in early infantile onset
“Statement #5: Hypotonia and delay in developmental motor milestones characterize the neurological manifestation of NPC in early infancy. Hepatosplenomegaly and/or prolonged neonatal jaundice are almost invariably noted, although cases with severe hypotonia in early infancy without obvious visceral disease can occur. Pulmonary disease may also be present.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Motor and developmental symptoms: early infantile onset in a French cohort
“Data available on all NP-C patients with early infantile neurological onset diagnosed in France between 1990 and 2013 were compiled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients in the present EI-NP-C series began neurological symptoms before 18 months of age” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“only few patients temporarily acquired autonomous walking, and none did acquire a fully normal gait.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypotonia and motor development delay were the first neurological sign in 85% of the patients, ataxia, and psychomotor regression in the remaining 15%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Motor and developmental symptoms: clumsiness, gait disturbance, and speech delay in late infantile onset
“Statement #6: Clumsiness, gait disturbance, and fine motor skill impairments characterize this age of disease onset. Speech delay, a history of neonatal cholestasis, seizures, pulmonary disease, variable visceromegaly, and failure to reach or loss of developmental milestones may be noted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Motor and developmental symptoms: developmental milestone delay by age at neurological onset in the registry
“Of the 46 patients where data is available, the most common manifestations were delay/impairments in: cognition (69.6%), speech (60.9%), motor (60.9%) and social (45.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In respect to neurological classification, speech delay was most common in early infantile (91.7%), whilst cognitive impairment was most common in late infantile (78.9%) and adult (100%), with motor delay (33.3%) and cognitive impairment (33.3%) predominant in juvenile onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurological symptoms: frequency of neurological manifestations in the registry
“The most common neurological manifestations reported include cognitive impairment (78.5%), dysarthria (75.9%), ataxia (75.9%), vertical supranuclear gaze palsy (VSGP) (70.9%), dysphagia (69.6%), dystonia (53.2%), seizures (48.1%), and cataplexy (35.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the late infantile onset subgroup made up the highest proportion of neurological manifestations, with the exception of psychiatric manifestations and cognitive impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The least prevalent neurological manifestations were psychiatric manifestations (13.9%) and hearing impairment (7.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oculomotor symptoms: vertical supranuclear saccadic palsy and gaze palsy
“Vertical supranuclear saccadic palsy (VSSP), followed later by vertical supranuclear gaze palsy (VSGP), is typically present but often unrecognized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seizures and gelastic cataplexy
Movement disorder and bulbar symptoms: dystonia, dysarthria, and dysphagia
Auditory symptoms: hearing loss in 50 patients with NPC1
“Data from 50 patients with NPC1 confirm a prevalent, often high frequency, hearing loss that is progressive in at least some individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retrocochlear involvement is common, and some patients present with a profile of auditory neuropathy spectrum disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, of the 31 patients with behavioral data, 23 (74%) presented with clinically significant hearing loss involving the frequencies most important to speech understanding (500–4000 Hz).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Auditory symptoms: sensory deafness as a first symptom in late infantile onset
Cognitive symptoms: progressive cognitive impairment in childhood
Cognitive and psychiatric symptoms: juvenile and adult onset
“Statement #7: Juvenile onset manifests as cognitive impairment (lagging behind peers in school, language and learning difficulties), coordination problems (clumsiness, frequent falls, progressive ataxia, and dystonia), seizures, and VSGP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cognitive impairment invariably occurs and tends to present with higher rates of psychiatric illness alongside neurological manifestations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Dysphagia and nutritional support in early infantile onset
“Many data were missing in the later follow-up of patients (Table 3) but by order of frequency, neurological manifestations included: swallowing troubles (18 patients, 16 of whom required enteral feeding by nasogastric tube or gastrostomy, all before 3 years of age), limb hypertonia (18 patients), cerebellar signs (16 patients), VSGP (14 patients), seizures (12 patients), neuropathic pain (9 patients), gelastic cataplexy (7 patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As for later onset NP-C forms, swallowing troubles were very frequent in EI-NP-C patients, with a need of nutritional support for 88% of untreated patients and 100% of miglustat treated patients, at a similar median age of 2.75 and 2.92 years respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lower limbs were more severely involved than upper limbs, and medications were poorly efficient using antispastic, antidystonic and antalgic drugs in more than 75% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dysphagia and aspiration across the disease course
“Dysphagia occurs in most NP-C patients at some point in the disease course, ranging in severity from occasional swallowing difficulties to loss of swallowing function necessitating placement of a nasogastric tube or gastrostomy feeding” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Silent aspiration in the NIH NPC1 natural history study
“We aimed to characterize aspiration and silent aspiration in the National Institutes of Health (NIH) NPC1 Natural History Study (NCT00344331).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Silent aspiration occurred in 24/130 (18.4%) participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Considering aspiration risk, 27/130 (20.8%) had NIH-PAS > 1, including all silent aspirators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean time to silent aspiration was ~ 10 years from neurologic symptom onset, with no difference by neurological disease onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Silent aspiration is common in NPC1 and closely linked to advancing neurologic disease severity than to age-of-onset phenotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Functional disability by domain in the registry
“A 6-domain composite disability scale was used to calculate the overall disability score for each neurological form.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all with neurological onset, the majority of patients showed moderate to severe impairments in all domains, except for ‘swallowing’ and ‘seizure’.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The composite disability scores were notably higher in patients with early onset neurological signs, particularly in late infantile patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic liver disease, fibrosis, and hepatocellular carcinoma after neonatal liver disease
“Higher liver stiffness measurement scores, suggesting increased risk for liver fibrosis, were associated with a history of significant liver disease in infancy (p = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, individuals who had severe liver disease at birth are at higher risk for developing clinically significant liver disease after the neonatal period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given multiple reports of hepatocellular carcinoma in individuals with NPC1, those with a history of severe liver disease should be closely monitored.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrointestinal, liver, and other comorbidities in the 2025 guideline
“NPC has the highest early onset penetrance of Crohn's among monogenic diseases due to patients' predisposition to intestinal inflammation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although rare in childhood, patients with NPC might have an increased risk of hepatocellular carcinoma (HCC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with NPC are at increased risk of hypersalivation/drooling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is an increased prevalence of behavioral problems and other psychiatric disorders, such as anxiety, depression, or psychosis, in NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progressive dementia and death from aspiration pneumonia in childhood-onset disease
Burden of Niemann-Pick disease type C
Humanistic burden and health-related quality of life
Effects on wellbeing and quality of life in the 2025 guideline
Survey and interviews of caregivers and adult patients in the United States and United Kingdom
“A survey of caregivers for patients with NPC and adult patients with NPC (n = 49; patient age: 13 months–65 years) assessed NPC severity, importance of NPC symptoms, and how symptoms impacted patients’ and caregivers’ activities of daily living (ADLs) and health-related QOL (HRQOL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 49 surveys were completed across two countries: 37 in the US and 12 in the United Kingdom (UK).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Findings indicated that the most important manifestations of NPC were ambulation, swallowing, speech, fine motor skills, and cognition, which were those that had the most significant impact on ADLs and HRQOL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ADLs and HRQOL were impaired in the majority of patients as well as their caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The findings were independent of current age, age of onset of symptoms, and level of NPC disease-related disability; however, the impact increased at higher levels of disease disability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient HRQOL domains affected, from the caregiver perspective
“NPC and the impact it has upon ADLs also has a further effect upon patients’ HRQOL in a number of ways, with considerable impact on all major domains of HRQOL: emotional (n = 26; 92.9%), physical (n = 24; 85.7%), psychological (n = 10; 35.7%), and social (n = 22; 78.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants reported feelings of social isolation, loss of enjoyment in activities (patients), and feelings of sadness or worry (caregivers).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver HRQOL
“The impact of NPC on caregivers’ HRQOL was reported by many participants (n = 15; 53.6%) as summarized in Table 7, which also presents example quotes to illustrate the impact.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Emotional impacts were those most commonly reported by caregivers, who discussed feelings of sadness, worry, anxiety, or distress about the impacts NPC was having on the patient, and reported feeling they were always on alert, being concerned about the patient suffering an injury, illness, or deteriorating due to their NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Focus groups with 19 patients and caregivers
“To further grasp patient and caregiver perceptions and experiences with NPC, we carried out focus group discussions with pediatric and adult individuals with NPC (N = 19), with partial or full representation of the patient by their caregiver.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Focus group discussions revealed that neurological signs, including declining cognition, memory loss, and psychiatric symptoms, as well as increasingly impaired mobility and motor function, are among the most pressing past and current concerns for patients and caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, several participants also expressed concern over a loss of independence, social exclusion, and uncertainty for what the future holds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease-specific proxy-rated quality-of-life scales for children and adults
“No scales currently exist to measure the impact of medication, physical therapy or clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NPC quality-of-life questionnaires for children (NPCQLQ-C) and adults (NPCQLQ-A) proxy prototype scales were produced and completed by 23 parents/carers of children (child age mean = 8.61 years) and 20 parents/carers of adults (adult age = 33.4 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reliability analysis resulted in a 15-item NPCQLQ-C and a 30-item NPCQLQ-A, which showed excellent internal consistency, Cronbach’s α = 0.925 and 0.947, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Generic HRQOL instrument scores in eight Dutch adults
“Eight patients with genetically confirmed NP-C were recruited from two Dutch University Medical Centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients scored significantly lower on physical domains of HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The health related quality of life in our cohort, measured with the RAND-36, was on several domains significantly lowered compared to the general population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Especially the general health perception was scored remarkably low, 35.0 on a scale of 0–100.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Cost of illness in the United Kingdom, 2007 survey
“In total, 18 Medical Resource Use questionnaires (29% response rate) were received and analysed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean total annual cost (SD) of NP-C per patient was 39,168 pounds (50,315 pounds); 46% were direct medical costs, to which home visits and residential care contributed 68% and 15%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If only direct medical costs were considered, the mean annual cost (SD) per patient was reduced to 18,012 pounds (46,536 pounds).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The direct annual per-patient cost of NP-C illness in 2007 appears moderate when compared with other rare and severely disabling diseases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, cost estimates may be conservative, since findings are limited by a small sample size, low survey response rate and potential recall bias.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Targeted review of economic evidence across Niemann-Pick disease types
Medication use in the International Niemann-Pick Disease Registry
Prescription adjudication and rejection rates for approved Niemann-Pick disease type C therapies
U.S. claims-based cost and resource use study of Niemann-Pick disease type C
No evidence found.
Economic impact of Niemann-Pick disease type C on families
Direct non-medical and indirect costs borne by patients and families in the United Kingdom
“Direct non-medical costs accounted for 24% of the average annual cost per patient, mainly due to specialist education, and indirect costs 30%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As demonstrated by this study, a substantial proportion of the cost is shifted from the healthcare system to the patient, family and non-medical providers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden and changes in employment
“Along with these impacts, there was an increased risk of experiencing dangerous or life-threatening situations leading to loss of patient independence and additional caregiver burden, often requiring changes in lifestyle such as giving up work.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 43 caregivers completing the survey, 40 were a parent of the patient, one sibling, one grandparent, and one aunt.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health insurance, Medicaid waivers, and access burden in a U.S. survey
“Of the 79 respondents who completed the survey, 67 participated in interviews.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, 61% of respondents were unaware of Medicaid waivers and did not avail of them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 50% of respondents with childhood onset NPC selected Medicaid/Medicare and private insurance; 35% utilized Medicaid waivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequently cited access burden was the process of obtaining medical care and services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Delays and denials in obtaining essential medication, equipment, and services contributed to disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers faced burnout and often questioned the utility of their advocacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket costs and financial assistance in a U.S. survey
“Most respondents (90%) did not have difficulty paying for their medical expenses; however, this may reflect lack of approved therapy or bias in the group that was studied.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Often, respondents mentioned paying high co-pays for drugs, especially miglustat, which is used off-label and costs approximately $58,000 per month and may not be covered by waivers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most respondents did not use a health savings account (68%) or seek financial assistance from co-pay support programs (92%), reduced payment programs (97%), free drug programs (95%), or nonprofit organizations (94%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket exposure for approved therapies under Medicare Part B
Family and carer burden in the Australian standard of care
“A formal diagnosis, once established, places a substantial burden on the whole family, the negative impact of which is far‐reaching.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Effective and optimal patient outcomes necessitate access to specialist multidisciplinary team (MDT) care, placing considerable societal, administrative and financial burden on the individual diagnosed with NP‐C, their family and carers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The burden of care coordination places significant strain on the carer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Public education and disability services for affected children in the United States
Economic impact of diagnostic testing
Medicare payment for NPC1 and NPC2 gene sequencing, 2026
Medicare payment for exome and genome sequencing, 2026
Cost-effectiveness of plasma oxysterol screening in intellectually disabled patients in Canada
“Our objective is to compare costs and outcomes of plasma oxysterol screening versus current practice in diagnosis of NP-C disease among intellectually disabled (ID) patients using decision-analytic methods.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The outcomes of the base case model showed that using plasma oxysterol screening for diagnosis of NP-C disease among ID patients is a dominant strategy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average amount of cost saving was $3642 CAD and the incremental QALYs per each individual ID patient in oxysterol screening arm versus current practice of diagnosis NP-C was 0.0022 QALYs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Gene panel cost and test selection in the Australian standard of care
“Multigene panels are becoming more accessible and cost‐effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When gene panel tests are used, they should be symptom‐specific and must include the NPC1 and NPC2 genes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer-sponsored exome testing at no charge in the United States
Approaches to treatment
Current treatment options and standard of care
Miglustat
Guideline recommendation: miglustat for all patients with a confirmed diagnosis
“Miglustat, a substrate reduction therapy, is licensed as a disease‐modifying medicine to treat the neurological manifestations of patients with NPC disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In some patients, miglustat has been shown to attenuate disease progression and improve survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #15: All patients with a confirmed diagnosis of NPC should be considered for miglustat therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strength of recommendation: 1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Level of evidence: B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expert's opinion: completely agree (44.83%), mostly agree (44.83%), partially agree (10.34%), partially disagree (0.00%), mostly disagree (0.00%), and completely disagree (0.00%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Candidates for miglustat and exclusions in GeneReviews
Approval for Niemann-Pick disease type C outside the United States and off-label use in the United States
“Miglustat, an inhibitor of glucosylceramide synthase, has been approved to treat NPC in other countries; however, its use remains off-label in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat has been shown to ameliorate neurological symptoms and extend survival but does not arrest disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomized controlled trial in participants aged 12 years or older and an uncontrolled pediatric cohort
“Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients aged 12 years or older who had NPC (n=29) were randomly assigned to receive either miglustat 200 mg three times a day (n=20) or standard care (n=9) for 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“12 children younger than 12 years of age were included in an additional cohort; all received miglustat at a dose adjusted for body surface area.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was horizontal saccadic eye movement (HSEM) velocity, based on its correlation with disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, HSEM velocity had improved in patients treated with miglustat versus those receiving standard care; results were significant when patients taking benzodiazepines were excluded (p=0.028).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Children showed an improvement in HSEM velocity of similar size at 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Improvement in swallowing capacity, stable auditory acuity, and a slower deterioration in ambulatory index were also seen in treated patients older than 12 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The safety and tolerability of miglustat 200 mg three times a day in study participants was consistent with previous trials in type I Gaucher disease, where half this dose was used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension in adult and juvenile participants
“All patients completing the randomized trial were allowed to continue treatment in a 12-month, non-controlled open-label extension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean horizontal saccadic eye movement velocity (HSEM-alpha) indicated improvement in the 12-month miglustat group, and stabilization in the 24-month group; swallowing was improved or stable in 86% and in up to 93%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ambulation was stabilized in both the 12- and 24-month groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an exploratory disease stability analysis of prospective data on key parameters of disease progression (HSEM-alpha, swallowing, ambulation and cognition), 13/19 (68%) patients receiving >or= 12 months' miglustat therapy had stable disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among all patients receiving >or= 1 dose of miglustat (n=28), the most frequent adverse events were diarrhoea, weight decrease, flatulence and tremor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension in children aged 4 to 12 years
“Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ten children completed 24 months' treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
International NPC Registry: disability during continuous miglustat therapy by age at neurological onset
“In total, 283 patients were enrolled from 28 centers in 13 European countries, Canada and Australia between September 2009 and October 2013; 92 patients received continuous miglustat therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 84 evaluable patients, 9 (11 %) had early-infantile (<2 years), 27 (32 %) had late-infantile (2 to <6 years), 30 (36 %) had juvenile (6 to <15 years) and 18 (21 %) had adolescent/adult (≥15 years) onset of neurological manifestations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Progression of composite disability scores appeared highest among patients with neurological onset during infancy or childhood and lowest in those with adolescent/adult-onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 59/86 evaluable patients (69 %) were categorized as improved/stable and the proportion of improved/stable patients increased with age at neurological onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival with and without miglustat: pooled national cohorts and the NPC Registry
“Overall, 384 (57.4%) patients in the Neurological onset group and 329 (55.8%) in the Diagnosis group were treated with miglustat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat treatment was associated with a significant reduction in the risk of mortality in neurological onset group patients (adjusted HR [95% CI] 0.510 [0.335, 0.777]; P < .01) (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effect was consistent across all four age‐at‐neurological‐onset sub‐groups, with a trend that favoured miglustat treatment; all HRs were between 0.364 (late infantile patients) and 0.671 (early infantile patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results were statistically significant for late infantile patients (HR [95% CI] 0.364 [0.165, 0.801]; P < .05); statistical significance was not achieved in the remaining age‐at‐neurological‐onset sub‐groups (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat treatment was associated with a significant reduction in the risk of mortality in diagnosis group patients (HR [95% CI] 0.441 [0.293, 0.664]; P < .001) (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, this study is the first exploratory analysis conducted in the largest pool of observational data for patients with NP‐C to date, treated in a real‐world setting and with a broad geographical representation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Swallowing outcomes in a single-center cohort with neurological onset before age 15 years
“Miglustat, a drug used off-label in the United States for the treatment of NPC1, appears to stabilize neurologic disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this cohort study of 50 individuals with Niemann-Pick disease, type C1 with neurologic disease onset before age 15 years, miglustat use was associated with stabilized swallowing function and reduced aspiration risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat use was associated with decreased odds of worse American Speech-Language-Hearing Association National Outcome Measurement System swallowing domain outcomes in all 3 subsets (overall: odds ratio [OR], 0.09 [95% CI, 0.02-0.36); P < .001; early childhood: OR, 0.17 [95% CI, 0.04-0.67]; P = .01; late childhood: OR, 0.05 [95% CI, 0.01-0.29]; P = .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat use was associated with decreased odds of worse Rosenbek aspiration-penetration scale outcomes in the overall cohort (OR, 0.28 [95% CI, 0.08-0.95]; P = .04) but not in each subgroup (early childhood: OR, 0.27 [95% CI, 0.06-1.22]; P = .09; late childhood: OR, 0.38 [95% CI, 0.06-2.33]; P = .29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infantile onset: French pediatric cohort treated in clinical practice
“Twenty children were enrolled; 19 had NPC1 gene mutations and 1 had NPC2 gene mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight NPC1 patients had the early-infantile, eight had the late-infantile, and three had the juvenile-onset forms of NP-C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NP-C disability scale scores indicated either stabilization or improvement of neurological manifestations in 1/8, 6/8, and 1/3 NPC1 patients in these subgroups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mild-to-moderate gastrointestinal disturbances were frequent during the first 3 months of miglustat therapy, but were easily managed with dietary modifications and/or anti-propulsive medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among early-infantile onset patients, a shorter delay between neurological disease onset and miglustat initiation was associated with an initial better therapeutic outcome in one patient, but miglustat did not seem to modify overall disease course in this subgroup.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early infantile onset: French retrospective comparison of treated and untreated patients
“Ten patients were included in the treated group (year of birth: 2006–2012), and 16 patients in the untreated group [born 1987–2005 (n = 15), 2012 (n = 1)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat therapy was started at a median age of 24.5 months (9–29) and median duration was 30 months (11–56).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events were reported in 7/10 patients on miglustat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients developed loss of psychomotor acquisitions or additional neurological symptoms despite miglustat therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Levacetylleucine
Guideline recommendation: levacetylleucine for patients with neurological symptoms
“Levacetylleucine (also known as L‐acetylleucine) is a modified amino acid derivative of leucine, approved by the FDA for treating neurological manifestations of NPC in both adult and pediatric patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #16: All patients with a confirmed diagnosis of NPC and neurological symptoms should be considered for levacetylleucine therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strength of recommendation: 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expert's opinion: completely agree (41.38%), mostly agree (37.93%), partially agree (17.24%), partially disagree (3.45%), mostly disagree (0.00%), and completely disagree (0.00%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product history: first FDA approval for Niemann-Pick disease type C in 2024
| Action date | Submission | Action type | Submission classification | Review priority; orphan status |
|---|---|---|---|---|
| “09/24/2024” | “ORIG-1” | “Approval” | “Type 1 - New Molecular Entity” | “PRIORITY; Orphan” |
Regulatory status outside the United States: European Union authorisation for Niemann-Pick disease type C
| Field | Quoted record |
|---|---|
| EMA product number | “EMEA/H/C/006327” |
| Marketing authorisation holder | “Intrabio Ireland Limited” |
| Opinion adopted | “13/11/2025” |
| Marketing authorisation issued | “19/01/2026” |
Change of ownership of the manufacturer in October 2026
Molecular target: prescribing information
Phase 2 open-label, rater-blinded trial in participants aged 6 years or older
“In this multi-national, open-label, rater-blinded Phase II study, patients were assessed during a baseline period, a 6-week treatment period (orally administered NALL 4 g/day in patients ≥ 13 years, weight-tiered doses for patients 6–12 years), and a 6-week post-treatment washout period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“33 subjects aged 7–64 years with a confirmed diagnosis of NPC were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NALL met the CI-CS primary endpoint (mean difference 0.86, SD = 2.52, 90% CI 0.25, 1.75, p = 0.029), as well as secondary endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No treatment-related serious adverse events occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 3 crossover trial: design and population in the prescribing information
SARA and fSARA treatment differences in the Niemann-Pick disease type C trial of levacetylleucine
“The primary end point was the total score on the Scale for the Assessment and Rating of Ataxia (SARA; range, 0 to 40, with lower scores indicating better neurologic status).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (±SD) change from baseline in the SARA total score was -1.97±2.43 points after 12 weeks of receiving NALL and -0.60±2.39 points after 12 weeks of receiving placebo (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Plain language summary of the phase 3 result in a state Medicaid drug evaluation
Open-label extension at 12 and 18 months compared with a historical cohort
“Fifty-three patients aged 5–67 years (45.3% female, 54.7% male) were enrolled in the EP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (±SD) baseline (visit 2) score on the 5-domain NPC-CSS was 11.10 (±4.73).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was −0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI −3.05 to −0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI −4.06 to −0.35; p = 0.023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analysis of pediatric vs adult patients demonstrated consistent benefit with NALL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No TEAEs occurred in more than 10% of patients on NALL, and no patients had TEAEs that were assessed by the investigator as related to NALL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Arimoclomol
Guideline recommendation: arimoclomol for patients with neurological symptoms on background miglustat
“Arimoclomol is a small‐molecule drug classified as a heat shock protein co‐inducer, targeting HSP70, approved by the FDA in combination with miglustat for the treatment of NPC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #17: All patients with a confirmed diagnosis of NPC and neurological symptoms using background miglustat treatment should be considered for arimoclomol therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expert's opinion: completely agree (37.93%), mostly agree (37.93%), partially agree (20.69%), partially disagree (3.45%), mostly disagree (0.00%), and completely disagree (0.00%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. regulatory history: complete response letter in June 2021
U.S. regulatory history: advisory committee vote in August 2024
U.S. approval in September 2024 in combination with miglustat
Phase 2/3 trial NPC-002: prespecified 5-domain NPCCSS primary endpoint
“In a 12‐month, prospective, randomised, double‐blind, placebo‐controlled, phase 2/3 trial (ClinicalTrials.gov identifier: NCT02612129), patients (2‐18 years) were randomised 2:1 to arimoclomol:placebo, stratified by miglustat use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was change in 5‐domain NPC Clinical Severity Scale (NPCCSS) score from baseline to 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty patients enrolled; 42 completed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At month 12, the mean progression from baseline in the 5‐domain NPCCSS was 0.76 with arimoclomol vs 2.15 with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A statistically significant treatment difference in favour of arimoclomol of −1.40 (95% confidence interval: −2.76, −0.03; P = .046) was observed, corresponding to a 65% reduction in annual disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the prespecified subgroup of patients receiving miglustat as routine care, arimoclomol resulted in stabilisation of disease severity over 12 months with a treatment difference of −2.06 in favour of arimoclomol (P = .006).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events occurred in 30/34 patients (88.2%) receiving arimoclomol and 12/16 (75.0%) receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fewer patients had serious adverse events with arimoclomol (5/34, 14.7%) vs placebo (5/16, 31.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment‐related serious adverse events (n = 2) included urticaria and angioedema.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2/3 trial NPC-002: rescored 4-domain NPCCSS introduced post hoc
“To more accurately assess changes in disease course over a 12-month time period in a heterogeneous group of patients, the Cognition domain was removed from the 5DNPCCSS and the Swallow domain was rescored to reflect linearity in disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NPC-002 post-hoc primary analysis showed a mean standard error (SE) change in R4DNPCCSS score of 0.35 (0.40) with arimoclomol (N = 34) versus 2.05 (0.54) with placebo (N = 16), and a treatment effect in favor of arimoclomol over placebo of −1.70 (p = 0.0155).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the miglustat subgroup analysis, mean (SE) change in R4DNPCCSS score was −0.23 (1.02) with arimoclomol (N = 22) versus 1.92 (3.37) with placebo (N = 12), representing a treatment effect of −2.21 (p = 0.0077).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2/3 trial NPC-002: results in the miglustat subgroup in the prescribing information
| R4DNPCCSS score | MIPLYFFA with miglustat (N=26 at baseline, N=22 at month 12) | Placebo with miglustat (N=13 at baseline, N=12 at month 12) |
|---|---|---|
| Baseline, mean (SD) | “8.9 (6.1)” | “7 (5.8)” |
| Change from baseline to month 12, mean (SD) | “-0.2 (1)” | “1.9 (3.4)” |
| Change from baseline to month 12, LS mean (SE) | “-0.2 (0.5)” | “2 (0.7)” |
| Placebo-subtracted difference (95% CI) | “-2.2 (-3.8, -0.6)” | Not applicable |
Appraisal of the phase 2/3 trial in a state Medicaid drug evaluation
Long-term data: 48-month open-label extension of NPC-002
“Of the 50 patients who started the DB phase, 41 entered the OLE phase, with 29 completing 48 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the OLE, mean (SD) 5DNPCCS and R4DNPCCSS scores increased by 3.2 (4.8) and 2.7 (4.2) over 48 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients switching from placebo to arimoclomol after the DB phase, mean annual change in 5DNPCCSS decreased from 2.0 (on placebo) to 0.1 in the first year of receiving arimoclomol and mean annual change in R4DNPCCSS decreased from 1.9 to 0.2, indicating slowing of disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The score pattern in the subset of patients who received miglustat as part of their standard care regime in addition to arimoclomol (N = 33) was similar to that seen in the total population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Arimoclomol was well-tolerated over 48 months, with no new safety concerns identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term data: U.S. early access program over 4 years
“Participants were enrolled at 14 US sites.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 109 participants, 53 (48.6%) were adults (≥18 years) and 71 (65.1%) received miglustat alongside arimoclomol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) arimoclomol exposure was 820 (539) days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 248 reported AEs, 17 events in 13 participants (12.8%) were treatment related.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“5DNPCCSS scores remained relatively stable throughout the program, with mean (SD) total scores of 11.0 (6.15) at Baseline (n = 100) and 12.0 (7.32) at Year 4 (n = 22).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Infants younger than 24 months: open-label pediatric substudy
“The dosing regimen used for patients <24 months differed from the regimen recommended in the FDA label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five patients (three females, two males; aged 14–23 months at screening) were enrolled; four remained in the study >12 months; arimoclomol exposure ranged from 72 to 1109 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients received concomitant miglustat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two AEs in one patient (elevated alanine/aspartate aminotransferases) were considered probably related to arimoclomol and resolved within 51 days; the patient was withdrawn from the substudy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further investigation in larger cohorts is warranted to elucidate the impact of arimoclomol in NPC patients under 2 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Planned supplemental application for infants younger than 24 months
Regulatory status outside the United States: refusal of European Union marketing authorisation confirmed in November 2026
Other cyclodextrin products
Guideline status of intrathecal and intravenous 2-hydroxypropyl-beta-cyclodextrin before the LEMBAZ approval
HPβCD products differ in composition: VTS-270 and Trappsol Cyclo
“VTS-270 (Kleptose HPB) and Trappsol® Cyclo™ are HPβCD products under investigation as novel treatments for NPC1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, HPβCD formulations are not comprised of a single molecular species, but instead are complex mixtures of species with differing degrees of hydroxypropylation of the cyclodextrin ring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the analytical differences observed between VTS-270 and Trappsol Cyclo with respect to the degree of substitution, the composition and fingerprint of the complex mixture, and the impurity profiles, these products cannot be considered to be the same; the potential biological and clinical implications of these differences are not presently known.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intravenous HPβCD (Trappsol Cyclo, remibetadex): sponsor and development status
Remibetadex NDA submitted October 2026 for neurovisceral manifestations from birth
Remibetadex regulatory timeline and anticipated FDA action
TransportNPC phase 3 trial of intravenous Trappsol Cyclo: design
TransportNPC primary endpoint at week 96: not statistically significant
TransportNPC safety over 96 weeks, including hearing-related adverse events
Company-presented infantile-onset survival analysis of Trappsol Cyclo with registry external controls
TransportNPC open-label pediatric sub-study in children under 3 years
Phase 1/2 trial of intravenous Trappsol Cyclo: design and outcomes at 48 weeks
“Twelve patients aged at least 2 years (2–39 years of age) with a confirmed diagnosis of NPC1 were randomized to receive one of three IV doses of HP-β-CD (1500 mg/kg, 2000 mg/kg, or 2500 mg/kg) every 2 weeks for 48 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients received HP-β-CD; there was no placebo or other control.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 9 patients who completed the study, 7 were viewed by their treating physicians as having improved to some degree at the end of the study, and 2 remained stable; both outcomes are highly relevant in a progressive neurodegenerative disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Australian standard of care: Trappsol Cyclo as the most advanced investigational cyclodextrin
“Of these, the cyclodextrin Trappsol Cyclo (Cyclo Therapeutics Inc., USA) is the most advanced.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further research is needed to determine the optimal role of these novel therapies in the clinical setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expanded access with intravenous HPβCD in the United States and Brazil
“HPβCD has been administered to NPC patients with approved INDs globally since 2009.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here we present safety, tolerability and efficacy data from 12 patients treated intravenously (IV) for over 7 years with HPβCD in the US and Brazil.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several patients transitioned to an alternate HPβCD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Severely affected patients demonstrated periods of stability but eventually showed progression of disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Compassionate use of intrathecal and intracerebroventricular HPβCD in Japan
“Herein, we describe the effects of intrathecal HPB-CD in an eight-year-old patient with a perinatal onset of NPC, administered initially at a dose of 10 mg/kg every other week and increased up to 10 mg/kg twice a week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two months later, no adverse effects were observed, thus we implanted an Ommaya reservoir to administer 20 mg/kg HPB-CD weekly thereafter (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To demonstrate long-term efficacy and safety of intrathecal HPBCD (IT-HPBCD) treatment for NPC, we herein reports five patients with NPC treated using IT-HPBCD for 4-11 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mild-to-moderate hearing loss was observed in three patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term treatment with IT-HPBCD may suppress neurological deterioration in patients with NPC; however, the treatment outcome is dependent on the neurological status at the time of diagnosis, and disease progression is not completely inhibited.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Single-patient intrathecal HPβCD under an individual IND in the United States
“The study drug was administered under an individual investigational new drug (IND) application filed with the FDA (IND 119,208).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The subject received 200mg intrathecal HP-β-CD administered biweekly via lumbar puncture.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The subject has developed subclinical hearing loss at high frequency that is likely HP-β-CD related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intrathecal HPβCD in a child with severe infantile-onset disease in Spain
“The initial dose of 175 mg was gradually increased over the first 6 months to reach 325 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intrathecal hydroxypropyl-β-cyclodextrin therapy is safe, but its efficacy seems questionable in a patient with the severe infantile form of Niemann-Pick disease type C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combined intrathecal and intravenous Trappsol Cyclo in two children in Greece
“Two preparations are commercially available: Trappsol®Cyclo™ and VTS-270.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High intrathecal (900mg) and low intravenous (350–500mg/kg) doses of HP-β-CD (Trappsol®Cyclo™) were administrated twice monthly to the patients in addition to miglustat therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The combination therapy of miglustat and HP-β-CD resulted in disease stabilization in both patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review assessment of HPβCD evidence
“HPβCD demonstrated biological target engagement, including changes in cholesterol-related biomarkers, but clinical findings were mixed: uncontrolled intrathecal and intravenous studies suggested stabilization or improvement, whereas controlled evidence was less supportive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hearing impairment remained an important safety concern.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HPβCD remains investigational because its biological activity has not translated into consistent controlled clinical benefit and requires careful safety monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Supportive and symptomatic care
Supportive care recommended with multidisciplinary specialist input
Supportive options described in a state Medicaid drug class review
Neurological symptoms: spasticity, cataplexy, and seizures
“Spasticity and spasms should be treated initially by non‐pharmacological means.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If these are unsuccessful, pharmacological agents, including baclofen, tizanidine, benzodiazepines, dantrolene sodium, and botulinum toxin injections, may be considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Protriptyline, other tricyclic agents, methylphenidate or modafinil may be efficacious for cataplexy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seizures should be treated by a neurologist aware of the disease, considering the possibility of aggravation with some anti‐seizure drugs like carbamazepine and vigabatrin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Swallowing and nutrition: dietary modification and gastrostomy
“Dietary modification and compensatory postures may be beneficial for individuals with dysphagia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Counseling individuals on the long‐term utility of assisted feeding by gastrostomy tube is recommended early in the disease to prevent delay and improve quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypersalivation and drooling
“Patients should be treated with established interventions, including postural drainage ±pharmacological agents such as hyoscine hydrobromide transdermal patches; glycopyrronium bromide orally, subcutaneously or via a gastrostomy and small doses of orally administered atropine, or parotid/submandibular glandular injections of botulinum toxin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mobility, movement disorders, and sleep
“Strategies to maintain optimal mobility and reduce falls, such as providing walking/mobility aids, ankle‐foot orthotics, and exercise programs, should be sought proactively to prolong mobility and transfer ability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transplantation and investigational therapies
Investigational agents and modalities named in the 2025 guideline
“Other experimental therapies include the orally administered agents efavirenz, a non‐nucleoside reverse transcriptase antiretroviral inhibitor, and nizubaglustat, a selective dual inhibitor of ceramide glucosyltransferase and non‐lysosomal neutral glucosylceramidase (NLGase)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, several other therapeutic modalities, including gene therapy, antisense oligonucleotide (ASO) therapy for patients with specific targetable mutations, and CRISPR/Cas9 technology in animal studies, are underway with positive preliminary findings” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gene and cell-based therapies remain preclinical
“Gene therapy and cell‐based therapies (mesenchymal stem cells) have gained much interest in the pre‐clinical setting,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but there have been no clinical trials to our knowledge to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nizubaglustat phase 3 trial in late-infantile and juvenile forms
Efavirenz phase 2 trial in adult and late juvenile-onset disease
“This is a single-center, phase II clinical trial to evaluate the efficacy and safety of Efavirenz in addition to standard of care in patients diagnosed with adult or late juvenile-onset NPC with cognitive impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All enrolled patients will be treated orally with 25 mg/d of Efavirenz for 52 weeks (1 year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review assessment of evidence for investigational agents
Allogeneic bone marrow transplantation in NPC2: case reports
“In this report we describe the first successful allogeneic bone marrow transplantation for this condition in a 16-month-old boy homozygous for the NPC2 p.E20X mutation, which has hitherto been reported to cause disease with a severe phenotype.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This 'graft versus substrate' reaction was managed with intensive immune suppressant therapy, and it gradually resolved as the substrate was cleared by the engrafted donor macrophages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast to the previously reported patients with the same mutations, our patient has no respiratory compromise and has made some developmental progress (especially gross motor), though is significantly delayed (particularly in speech and language).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Haematopoietic stem cell transplantation (HSCT) could be considered for patients with this mutation as long as performed early in the course of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver transplantation in children with neonatal liver failure: case series
“Nine children were identified (six centres).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neonatal acute liver failure was the most common indication for LTx (seven children).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological symptoms developed in 4/7 (57%) patients at median 9 (range: 5–13) years following LTx.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological disease is not prevented in the majority of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LTx still remains controversial in NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
- No currently available therapy for NPC is curative. Before the LEMBAZ approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death.
- Age and weight limits: FDA-approved treatments for the neurological manifestations of NPC are indicated only for patients 2 years of age or older (arimoclomol, in combination with miglustat) or weighing 15 kg or more (levacetylleucine), leaving limited options for early infantile-onset NPC. An open-label substudy of arimoclomol in infants younger than 24 months enrolled 5 participants aged 14 to 23 months, and the company anticipates filing a supplemental application for this age group in Q1 2027.
- Miglustat: miglustat is used off-label for NPC in the United States. In a comparison of 10 treated and 16 untreated individuals with early infantile NP-C, all treated patients developed loss of psychomotor acquisitions or additional neurological symptoms, and the authors report that “Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C”. In a pooled observational analysis, the hazard ratio for mortality with miglustat was 0.671 in early infantile patients, a result that did not achieve statistical significance, and 0.364 (95% CI 0.165, 0.801) in late infantile patients.
- Levacetylleucine: the randomized, placebo-controlled crossover trial enrolled 60 participants with a median age of 25 years (range 5 to 67 years) and treated each period for 12 weeks; the estimated treatment difference in the fSARA total score was -0.4 (95% CI -0.7, -0.2).
- Arimoclomol: efficacy was demonstrated in patients receiving background miglustat, with a placebo-subtracted difference in the rescored 4-domain NPCCSS of -2.2 (95% CI -3.8, -0.6) at month 12. The FDA determined that evidence for arimoclomol monotherapy was insufficient, and after re-examination on 12 November 2026 the European Medicines Agency confirmed its recommendation to refuse marketing authorisation for arimoclomol (Meplyffa).
- Evidence gaps: the arimoclomol and levacetylleucine trials did not address nonneurological manifestations such as liver disease, no published studies address coadministration of the two drugs, and data beyond 5 years are extremely limited. Differences in study design, outcome measures, and follow-up preclude direct comparison between therapies.
- Other cyclodextrin products: in the TransportNPC phase 3 trial of intravenous Trappsol Cyclo (remibetadex), the primary endpoint at Week 96 did not achieve statistical significance (p=0.19), and hearing-related adverse events occurred in 15.6% of participants receiving Trappsol Cyclo and 13.3% receiving placebo; an NDA was submitted on October 28, 2026. One analysis concluded that HPβCD remains investigational and that hearing impairment is an important safety concern.
- Supportive care: most other options are supportive in nature, and for many individuals clinical trial participation may be the only access to disease-modifying treatment.
No curative therapy and restricted access to combination treatment
“No currently available therapies for NPC are curative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improving the accessibility and affordability of novel therapies is crucial for enhancing patient outcomes in NPC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No therapy shown to reduce mortality before the LEMBAZ approval
Sponsor and investigator statements on limited options in infantile-onset disease
Evidence gaps for arimoclomol and levacetylleucine identified by the ACMG
“Neither trial addressed nonneurological manifestations, such as liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are no published studies of outcomes or safety addressing coadministration of arimoclomol and levacetylleucine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Available data for treatment of NPC with arimoclomol or levacetylleucine beyond 5 years are extremely limited; long-term outcomes are not known.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Evidence gaps identified in a state Medicaid drug class review
Limited access to disease-modifying therapy in the Australian standard of care
“Disease‐modifying treatment options for NP‐C are limited (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For many individuals, clinical trial participation may be the only way to access disease‐modifying treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With no cure and limited access to disease‐modifying therapy, optimal management in Australia comprises symptomatic treatment of clinical manifestations and ongoing monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review: therapies cannot be compared directly
Place in treatment, anticipated use, and care setting
Summary
- Indication: LEMBAZ is indicated to reduce the risk of mortality in adult and pediatric patients who weigh 7 kg or greater with NPC whose neurological manifestations started at less than 6 years of age. Safety and effectiveness have not been established in pediatric patients who weigh less than 7 kg or whose neurological manifestations started at 6 years of age or older.
- Position relative to other therapies: before this approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death. In the label's integrated survival analysis, longer overall survival was observed independent of baseline miglustat use. Published recommendations state that all patients with a confirmed diagnosis should be considered for miglustat, those with neurological symptoms for levacetylleucine, and those with neurological symptoms on background miglustat for arimoclomol; more than 75% of participants in the arimoclomol and levacetylleucine pivotal trials were taking miglustat. The company describes adrabetadex as “a foundational therapy that can be safely combined with other approved NPC treatments”, based on a safety profile generally similar with and without additional therapies.
- Anticipated use: the company states that approximately half of those living with NPC in the United States, 475 children, have infantile-onset NPC, and that early intervention can make the greatest difference.
- Care setting: LEMBAZ is administered intrathecally every two weeks over 1 to 2 minutes by, or under the supervision of, a healthcare provider experienced in performing lumbar punctures, with local anesthetic and sedation as indicated by the patient's clinical condition. A comprehensive audiology evaluation is performed before use. Lembaz is exclusively available through CuraScript SD by Evernorth and is billed in medical buy-and-bill settings without a product-specific HCPCS code. Published recommendations call for referral to a center with expertise in NPC wherever possible.
Guideline rationale for combination treatment
Guideline recommendation for referral to an expert center
Company-presented positioning of adrabetadex as a foundational therapy combined with other approved treatments
Intended use: early intervention in infantile-onset disease
Care setting: administration sites and treatment center preparation
Emerging NPC treatment paradigm described by a competing cyclodextrin sponsor
Heterogeneity of treatment effect
Company-presented survival by onset category and baseline miglustat use
Company-presented survival by baseline disease burden in infantile-onset disease
Company-presented disease progression by time from neurological onset to treatment
Neurological onset at 6 years or older: outside the approved indication
Background miglustat or leucine use and the intravenous HPβCD treatment effect in TransportNPC
Subtype differences for the other approved therapies: state Medicaid drug class review
Guideline statements on predicting treatment response by subtype
“Additionally, predicting patient treatment responses remains challenging, further supporting the potential benefits of a combined therapeutic approach” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future research priorities must focus on identifying the optimal timing for individual therapies during disease progression and understanding the most effective treatment combinations for various NPC patient subtypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Multidisciplinary follow-up and baseline assessment
“Statement #14: Patients with NPC exhibit multisystem disease manifestations and benefit from holistic, multidisciplinary follow‐up from physicians and allied HCPs with experience in this condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A baseline assessment at diagnosis is required to determine the current level of disease severity and retrospectively estimate the rate of progression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommended monitoring of swallowing, hearing, and cognition in the 2025 guideline
“The presence of dysphagia, aspiration and response to therapy should be documented at diagnosis and then every 6 months in children and every 12 months in adults if the patient is asymptomatic with stable disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hearing assessments should be performed at the time of diagnosis and every 12 months to document the presence of hearing loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with NPC benefit from regular evaluation of their cognitive function (at diagnosis and every 12 months), and consideration should be given to changes in their cognitive ability that may impact independence/school/work and daily living activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommended surveillance schedule in GeneReviews
| Concern | Evaluation | Frequency |
|---|---|---|
| Interval medical history | “Establish rate of disease progression.” | “Every 6 mos” |
| NPC clinical severity score | “Document progression & response to therapy of key disease features.” | “Every 6 mos” |
| Hearing impairment | “Audiometry for new-onset hearing loss or its progression” | “Every 12 mos” |
| Nutrition and feeding | “Document nutritional status, presence/progression of dysphagia, & aspiration risk.” | “Every 6 mos in children; in adults, frequency could be ↓ to every 12 mos if asymptomatic & disease is stable” |
Care coordination and social work support
“Disease‐specific patient care is primarily conducted within the tertiary setting, with allied health, disability support services and general medical care occurring in a variety of external settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MDT should strive to provide individuals with NP‐C and their carers with a single treatment plan that accounts for regular assessments, examinations and medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proactive swallowing surveillance for silent aspiration
“Our findings support proactive swallowing surveillance in patients with NPC1, including consideration of routine instrumental evaluations (VFSS or FEES) even in the absence of overt clinical symptoms, particularly as neurologic severity increases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transition to adult services and palliative care planning
“Statement #20: Most children with late infantile and juvenile onset NPC are expected to reach adulthood with complex medical and psychosocial needs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The transition from pediatric to adult services should begin early and requires appropriate services in the community to provide a seamless transition from childhood to adult life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #21: Specialist center care providers, family physicians/pediatricians, and local palliative care services should develop close working links to support individuals and families with NPC throughout their lifespan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Audiology monitoring during LEMBAZ treatment described for families
Peer support for families considering LEMBAZ
Other product development or post-marketing obligations required by the FDA
Postmarketing commitment 5103-1: leachables data for the container closure system
Labeling and reporting obligations in the approval letter
Rare pediatric disease priority review voucher: marketing condition
Ongoing post-approval monitoring
Rare pediatric disease priority review voucher: post-approval report
Annual status reports on the postmarketing commitment
Real-world evidence generation planned by the manufacturer
Registered post-approval studies
No evidence found.
Expected outcomes of therapy
Summary
- Treatment goals: disease-modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and extending lifespan beyond that predicted by natural history data. Treatment goals are established at diagnosis and reviewed regularly, aiming to improve or maintain physical and psychosocial wellbeing.
- Survival in the label analysis: the FDA examined the survival of 36 participants treated with Lembaz across three clinical studies and an expanded access program against a matched external control group. Deaths occurred in 12 (33.3%) LEMBAZ-treated participants and 24 (66.9%) controls; the hazard ratio for death was 0.45 (95% CI 0.21, 0.95), a 55% reduction in the risk of death, and median survival was 8.5 years with treatment and 4.9 years in controls. Longer overall survival was observed independent of baseline miglustat use.
- Survival in a separate company analysis: deaths occurred in 17 (23.6%) adrabetadex-treated participants and 44 (61.2%) external controls, with a hazard ratio of 0.289 (95% CI 0.141, 0.593; P < 0.0001), reported by the company as a 71% reduction in the risk of mortality; the 5-year survival rate was 84% with adrabetadex and 42% in external controls.
- Disease progression: in a company analysis of 79 treated participants, the annual rate of progression on the rescored 4-domain NPCCSS fell from 1.34 units/year before treatment to 0.76 units per year after treatment, a 43% reduction (P=0.0055). An observational cohort receiving routine clinical care progressed by 1.5 units/year on the 5-domain NPCCSS. The company approval announcement states: “Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical”. Among five individuals treated with intrathecal HPBCD for 4 to 11 years, some disease progression continued.
- Expected harm: treatment with LEMBAZ has resulted in permanent hearing impairment; 37% (22/59) of patients in Trial 3 and an expanded access program experienced hearing impairment.
Guideline definition of disease-modifying therapy
“For the purpose of this paper, disease‐modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and ultimately extending lifespan beyond that predicted by available natural history data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To understand the effects of disease‐modifying therapy in NPC, information about the natural history of disease progression is required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline treatment goals and follow-up
“Statement #19: NPC is a progressive condition, and patients require regular follow‐up to monitor disease severity, treatment response, and recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment goals should be established at diagnosis and reviewed regularly, aimed at improving or maintaining the physical and psychosocial wellbeing of individuals with NPC and their families.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote